A novel triptolide analog downregulates NF-kB and induces mitochondrial apoptosis pathways in human pancreatic cancer

  1. Qiaomu Tian
  2. Peng Zhang
  3. Yihan Wang
  4. Youhui Si
  5. Dengping Yin
  6. Christopher R Weber
  7. Melissa L Fishel
  8. Karen E Pollok
  9. Bo Qiu
  10. Fei Xiao
  11. Anita S Chong  Is a corresponding author
  1. University of Chicago, United States
  2. Cinkate Pharmaceutical Corp, China
  3. Indiana University, United States

Abstract

Pancreatic cancer is the seventh leading cause of cancer-related death worldwide, and despite advancements in disease management, the 5-year survival rate stands at only 12%. Triptolides have potent anti-tumor activity against different types of cancers, including pancreatic cancer, however poor solubility and toxicity limit their translation into clinical use. We synthesized a novel pro-drug of triptolide, (E)-19-[(1'-benzoyloxy-1'-phenyl)-methylidene]-Triptolide (CK21), which was formulated into an emulsion for in vitro and in vivo testing in rats and mice, and using human pancreatic cancer cell lines and patient-derived pancreatic tumor organoids. A time-course transcriptomic profiling of tumor organoids treated with CK21 in vitro was conducted to define its mechanism of action, as well as transcriptomic profiling at a single time point post-CK21 administration in vivo. Intravenous administration of emulsified CK21 resulted in the stable release of triptolide, and potent anti-proliferative effects on human pancreatic cancer cell lines and patient-derived pancreatic tumor organoids in vitro, and with minimal toxicity in vivo. Time course transcriptomic profiling of tumor organoids treated with CK21 in vitro revealed <10 differentially expressed genes (DEGs) at 3 h and ~8,000 DEGs at 12 h. Overall inhibition of general RNA transcription was observed, and Ingenuity pathway analysis together with functional cellular assays confirmed inhibition of the NF-κB pathway, increased oxidative phosphorylation and mitochondrial dysfunction, leading ultimately to increased reactive oxygen species (ROS) production, reduced B-cell-lymphoma protein 2 (BCL2) expression, and mitochondrial-mediated tumor cell apoptosis. CK21 is a novel pro-drug of triptolide that exerts potent anti-proliferative effects on human pancreatic tumors by inhibiting the NF-κB pathway, leading ultimately to mitochondrial-mediated tumor cell apoptosis.

Data availability

Sequencing data have been deposited in GEO under Accession code GSE225011

The following data sets were generated

Article and author information

Author details

  1. Qiaomu Tian

    Department of Surgery, University of Chicago, Chicago, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4267-7362
  2. Peng Zhang

    Cinkate Pharmaceutical Corp, Shanghai, China
    Competing interests
    Peng Zhang, was an employee of Cinkate Pharmaceutical Corp. Is listed as an inventor on Patent WO2018/019301A1, which covers the design and use of CK21 for pancreatic cancer..
  3. Yihan Wang

    Department of Surgery, University of Chicago, Chicago, United States
    Competing interests
    No competing interests declared.
  4. Youhui Si

    Department of Surgery, University of Chicago, Chicago, United States
    Competing interests
    No competing interests declared.
  5. Dengping Yin

    Department of Surgery, University of Chicago, Chicago, United States
    Competing interests
    No competing interests declared.
  6. Christopher R Weber

    Department of Pathology, University of Chicago, Chicago, United States
    Competing interests
    No competing interests declared.
  7. Melissa L Fishel

    Department of Pediatrics, Indiana University, indianapolis, United States
    Competing interests
    No competing interests declared.
  8. Karen E Pollok

    Department of Pediatrics, Indiana University, indianapolis, United States
    Competing interests
    No competing interests declared.
  9. Bo Qiu

    Cinkate Pharmaceutical Corp, Shanghai, China
    Competing interests
    Bo Qiu, was an employee of Cinkate Pharmaceutical Corp..
  10. Fei Xiao

    Cinkate Pharmaceutical Corp, Shanghai, China
    Competing interests
    Fei Xiao, is listed as an inventor on Patent WO2018/019301A1, which covers the design and use of CK21 for pancreatic cancer..
  11. Anita S Chong

    Department of Surgery, University of Chicago, Chicago, United States
    For correspondence
    achong@uchicago.edu
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0460-0196

Funding

Cinkate Pharmaceutical Corp

  • Anita S Chong

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All animal experiments were approved by the Institutional Animal Care and Use Committee at the University of Chicago, and adhered to the standards of the NIH Guide for the Care and Use of Laboratory Animals. Pancreatic tumors from patients with pancreatic ductal adenocarcinoma were collected under University of Chicago IRB12-1108 and IRB13-1149.

Copyright

© 2023, Tian et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,082
    views
  • 225
    downloads
  • 7
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Qiaomu Tian
  2. Peng Zhang
  3. Yihan Wang
  4. Youhui Si
  5. Dengping Yin
  6. Christopher R Weber
  7. Melissa L Fishel
  8. Karen E Pollok
  9. Bo Qiu
  10. Fei Xiao
  11. Anita S Chong
(2023)
A novel triptolide analog downregulates NF-kB and induces mitochondrial apoptosis pathways in human pancreatic cancer
eLife 12:e85862.
https://doi.org/10.7554/eLife.85862

Share this article

https://doi.org/10.7554/eLife.85862

Further reading

    1. Cancer Biology
    2. Computational and Systems Biology
    Rosalyn W Sayaman, Masaru Miyano ... Mark A LaBarge
    Research Article Updated

    Effects from aging in single cells are heterogenous, whereas at the organ- and tissue-levels aging phenotypes tend to appear as stereotypical changes. The mammary epithelium is a bilayer of two major phenotypically and functionally distinct cell lineages: luminal epithelial and myoepithelial cells. Mammary luminal epithelia exhibit substantial stereotypical changes with age that merit attention because these cells are the putative cells-of-origin for breast cancers. We hypothesize that effects from aging that impinge upon maintenance of lineage fidelity increase susceptibility to cancer initiation. We generated and analyzed transcriptomes from primary luminal epithelial and myoepithelial cells from younger <30 (y)ears old and older >55 y women. In addition to age-dependent directional changes in gene expression, we observed increased transcriptional variance with age that contributed to genome-wide loss of lineage fidelity. Age-dependent variant responses were common to both lineages, whereas directional changes were almost exclusively detected in luminal epithelia and involved altered regulation of chromatin and genome organizers such as SATB1. Epithelial expression variance of gap junction protein GJB6 increased with age, and modulation of GJB6 expression in heterochronous co-cultures revealed that it provided a communication conduit from myoepithelial cells that drove directional change in luminal cells. Age-dependent luminal transcriptomes comprised a prominent signal that could be detected in bulk tissue during aging and transition into cancers. A machine learning classifier based on luminal-specific aging distinguished normal from cancer tissue and was highly predictive of breast cancer subtype. We speculate that luminal epithelia are the ultimate site of integration of the variant responses to aging in their surrounding tissue, and that their emergent phenotype both endows cells with the ability to become cancer-cells-of-origin and represents a biosensor that presages cancer susceptibility.

    1. Cancer Biology
    Yiwei Huang, Gujie Wu ... Cheng Zhan
    Research Article

    Chemotherapy is widely used to treat lung adenocarcinoma (LUAD) patients comprehensively. Considering the limitations of chemotherapy due to drug resistance and other issues, it is crucial to explore the impact of chemotherapy and immunotherapy on these aspects. In this study, tumor samples from nine LUAD patients, of which four only received surgery and five received neoadjuvant chemotherapy, were subjected to scRNA-seq analysis. In vitro and in vivo assays, including flow cytometry, immunofluorescence, Seahorse assay, and tumor xenograft models, were carried out to validate our findings. A total of 83,622 cells were enrolled for subsequent analyses. The composition of cell types exhibited high heterogeneity across different groups. Functional enrichment analysis revealed that chemotherapy drove significant metabolic reprogramming in tumor cells and macrophages. We identified two subtypes of macrophages: Anti-mac cells (CD45+CD11b+CD86+) and Pro-mac cells (CD45+CD11b+ARG +) and sorted them by flow cytometry. The proportion of Pro-mac cells in LUAD tissues increased significantly after neoadjuvant chemotherapy. Pro-mac cells promote tumor growth and angiogenesis and also suppress tumor immunity. Moreover, by analyzing the remodeling of T and B cells induced by neoadjuvant therapy, we noted that chemotherapy ignited a relatively more robust immune cytotoxic response toward tumor cells. Our study demonstrates that chemotherapy induces metabolic reprogramming within the tumor microenvironment of LUAD, particularly affecting the function and composition of immune cells such as macrophages and T cells. We believe our findings will offer insight into the mechanisms of drug resistance and provide novel therapeutic targets for LUAD in the future.